An update on VEXAS syndrome
A Al-Hakim, S Savic - Expert Review of Clinical Immunology, 2023 - Taylor & Francis
Introduction VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome
is a recently described, late-onset, acquired autoinflammatory disorder caused by mutations …
is a recently described, late-onset, acquired autoinflammatory disorder caused by mutations …
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
T De Witte, D Bowen, M Robin… - Blood, The Journal …, 2017 - ashpublications.org
An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
L Malcovati, E Hellström-Lindberg… - Blood, The Journal …, 2013 - ashpublications.org
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …
an Expert Panel was selected according to the framework elements of the National Institutes …
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation
ML Sorror, RF Storb, BM Sandmaier… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Age has long been used as a major factor for assessing suitability for allogeneic
hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was …
hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was …
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell
transplantation (HCT) in adults≥ 70 years with hematologic malignancies across the United …
transplantation (HCT) in adults≥ 70 years with hematologic malignancies across the United …
Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized …
Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative
conditioning regimen (MAC) before allogeneic transplantation in patients with …
conditioning regimen (MAC) before allogeneic transplantation in patients with …
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation
MG Della Porta, A Gallì, A Bacigalupo… - Journal of clinical …, 2016 - ascopubs.org
Purpose The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and
various combinations of somatic mutations are associated with different clinical phenotypes …
various combinations of somatic mutations are associated with different clinical phenotypes …
Guidelines for the diagnosis and management of aplastic anaemia.
JCW Marsh, SE Ball, J Cavenagh… - British journal of …, 2009 - search.ebscohost.com
The article presents the guideline for the diagnosis and management of aplastic anaemia. It
aims to provide healthcare professionals with clear guidance on the diagnosis and …
aims to provide healthcare professionals with clear guidance on the diagnosis and …
Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults
YL Kasamon, J Bolaños-Meade, GT Prince… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or
marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated …
marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated …
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic …
Context A minimally toxic nonmyeloablative regimen was developed for allogeneic
hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic …
hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic …